MA-ASPECT
29.7.2020 15:02:13 CEST | Business Wire | Press release
Today, Aspect announced the general availability of Aspect® Unified IP® and Advanced List Management™ 7.4 SP1, the latest release of its comprehensive, omnichannel customer engagement platform for managing experiences across service, collections and sales. This upgrade provides major enhancements in usability to deliver a modern user experience, making it easier to use for agents, managers and administrators use. The 7.4 SP1 release also builds upon Aspect’s outbound market leadership by adding new capabilities to help customers operate outbound contact centers efficiently, effectively and in compliance with national, regional and local regulations.
“Aspect Unified IP is the premier inbound and outbound enterprise contact center solution available in the market, and has been for over 14 years. The world’s top brands depend on Unified IP every day, and we are committed to continued development and offering new capabilities to help companies build lifetime loyalty among their consumers,” said Michael Harris, Chief Product Officer and CMO at Aspect.
Aspect Unified IP and Advanced List Management deliver advanced customer engagement capabilities that drive profitability and customer loyalty for many of the largest enterprises in financial, communications, retail, healthcare, and customer service around the world. Aspect remains committed to building upon and maintaining this essential platform. This release features improvements to the user interface such as:
- Improves the user interface for agents, managers and administrators into a consolidated, intuitive design across a variety of functions
- Provides managers, supervisors and administrators an improved user experience with quicker access to configuration tools, real-time data and alerts
- Refreshing third party tech so customers can stay current with security, compliance and IT protocols
“Aspect Unified IP provides best-in-class functionality and uptime for our entire organization including collections, customer service, back office, loan origination, and service desk. It is both an effective and efficient solution for our contact center and customer engagement needs,” said Michael Montgomery, VP Contact Center Solutions Exeter Finance
In the face of a global recession, the importance of outbound dialing and collections will steadily rise across industries. Aspect offers the only comprehensive outbound contact center solutions that allow the world’s largest organizations to effectively conduct proactive outreach activities while maintaining compliance with complicated regional, local, and national regulatory requirements. Aspect Unified IP and Advanced List Management are well equipped to help organizations adapt to the new challenges posed by this recession, and with the 7.4 SP1 release, additional capabilities have been added to ALM’s extensive tool set such as:
- Functionality to help improve operational efficiency, allowing organizations to smooth out dialing and reach more customers in a shorter period of time
- Goal-driven rules to ensure dialing aligns with an overall outreach strategy
- Security and auditing features to help maintain compliance with relevant regulations
- The ability to play specific messages for each attempt, creating more effective customer experiences while improving operational efficiency by minimizing repeat interactions
“City of Mesa has been on the Aspect Unified IP platform for six-plus years now since upgrading from legacy Aspect CallCenter® ACD. Like its predecessor, it has been a rock solid/stable platform in support of both standard hours and 24x7 services. The ease of being able to stand up new departments on the platform for remote workers during this time has proven to be invaluable,” said Richard Sandoval, Senior Unified Communications Engineer City of Mesa.
FIND OUT MORE about Aspect Unified IP and Advanced List Management.
About Aspect
Aspect is on a mission to simplify and improve customer engagement. Our enterprise software is used by millions of agents every year and supports billions of consumer interactions around the world. Our best-of-breed contact center and workforce optimization applications help companies keep agents engaged while providing exceptional customer service experiences. Our flexible, highly scalable solutions for self-service and live interaction management and workforce optimization are available on-premises or in any hosted, private or public cloud environment.
For more information, visit www.aspect.com . Follow Aspect on Twitter at @AspectSoftware. Read our blogs at http://blogs.aspect.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005568/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom